Publications by authors named "Fred Oldham"

Claim this Profile
P
Procoagulant inhibitory properties of paclitaxel poliglumex.
John Nemunaitis, Neil Senzer, Barry Cooper, Michael Nemunaitis, Cynthia Bedell, Fred B Oldham

Int J Gen Med· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
Rogerio Lilenbaum, Victoria M Villaflor, Corey Langer, Kenneth O'Byrne, Mary O'Brien, Fred B Oldham

J Thorac Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.
Claire F Verschraegen, Keith Skubitz, Adil Daud, Andrzej P Kudelka, Ian Rabinowitz, Fred B Oldham

Cancer Chemother Pharmacol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Mary E R O'Brien, Mark A Socinski, Alexander Y Popovich, Igor N Bondarenko, Antoaneta Tomova, Fred B Oldham

J Thorac Oncol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Corey J Langer, Kenneth J O'Byrne, Mark A Socinski, Sergei M Mikhailov, Krzysztof Leśniewski-Kmak, Fred B Oldham

J Thorac Oncol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.
Stewart D Chipman, Fred B Oldham, Gabriella Pezzoni, Jack W Singer

Int J Nanomedicine· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
John Nemunaitis, Casey Cunningham, Neil Senzer, Megan Gray, Fred Oldham

Cancer Invest· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study.
Donald A Richards, Paul Richards, David Bodkin, Marcus A Neubauer, Fred Oldham

Clin Lung Cancer· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuity of research outcomes: the correlation of bench toxicity mechanisms to clinical outcomes--are they dependable?
Fred B Oldham

Am J Kidney Dis· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis